CALLABLE MULTI DEFENDER VONTI - ELI LILLY & CO/BIOGEN IDEC | Real-time Bid/Ask 10:09:22 2024-05-17 am EDT | ||
| 100.2 USD / 101 USD | -0.49% |
|
| 1 month | +8.01% | ||
| 3 months | +3.06% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 24-05-15 | 101.1 | +0.60% |
| 24-05-13 | 100.5 | +0.40% |
| 24-05-10 | 100.1 | +0.40% |
Delayed Quote Swiss Exchange
Last update May 15, 2024 at 11:20 am EDT
More quotesStatic data
| Product type | Reverse Convertibles |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
Vontobel
|
| RMBI5V | |
| ISIN | CH1262670503 |
| Date issued | 2023-05-26 |
| Strike | 425.8 $ |
| Maturity | 2024-11-26 (193 Days) |
| Parity | 0.43 : 1 |
| Emission price | 100 $ |
| Emission volume | N/A |
| Settlement | both |
| Currency | USD |
Technical Indicators
| Highest since issue | 101.1 $ |
|---|---|
| Lowest since issue | 91 $ |
| Spread | 8 $ |
| Spread % | 0.79% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
771.1
USD
Average target price
850.4
USD
Spread / Average Target
+10.28%
- Stock Market
- Certificates
- RMBI5V Certificat